117 results
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
communication strategy and community engagement.
SAGE reviewed data across 19 Phase 1, 2 and 3 trials with more than 28,000 children and adults, including … strategy for enhancing our R&D pipeline. Our strategy to expand and diversify our external partnerships allows us to take part in research of a wide
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:18am
, Mr. Furuta served as corporate strategy officer and chief of staff at Takeda, and has held multiple leadership roles with the company around
6-K
TAK
Takeda Pharmaceutical Co
16 Jan 24
Current report (foreign)
6:01am
The Company Split is part of Takeda’s strategy to streamline the ownership structure of its subsidiaries and create a more adaptable and robust product
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
14 Dec 23
Current report (foreign)
6:01am
contributes to the corporate value of the Company Group by considering the Company’s mid-to-long term business strategy, and comparing the benefits … of the review, the Company divests shares from shareholdings that are deemed to be of little significance after taking the financial strategy and market
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
introduction should be accompanied by a well-designed communication strategy and community engagement.
SAGE reviewed data across 19 Phase 1, 2 and 3 … partnerships with third-party partners are a key component of our strategy for enhancing our R&D pipeline. Our strategy to expand and diversify our external
6-K
tnk80
1 Aug 23
Current report (foreign)
6:10am
6-K
EX-99.1
0eo6f95ol1
12 Jul 23
Current report (foreign)
6:07am
6-K
EX-99.1
bvkabghj1xykjk
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
7b0 qjnoq0d86
23 Jun 23
Current report (foreign)
6:13am
6-K
jtc311wf rg51dp
9 Jun 23
Current report (foreign)
6:03am
6-K
8n8r jcoz
30 May 23
Current report (foreign)
6:20am
6-K
EX-99.1
worzrk53h9
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
f7a 75h762sxq
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
ref57gz t0
30 May 23
Current report (foreign)
6:11am
6-K
4wa3rauelu xx
11 May 23
Current report (foreign)
6:07am
6-K
ht5 ihgc9i
30 Mar 23
Current report (foreign)
6:19am
6-K
EX-99.1
3lady9v
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
qr81n8k2vrswgm
30 Nov 22
Current report (foreign)
6:28am